About Pharmacyclics

Building a pipeline of novel drugs

Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases of critical unmet needs. We currently have four proprietary drug candidates under clinical development and two drug candidates under preclinical ClosePreclinical

Studies done in animals or in cell cultures prior to testing a new drug in human clinical trials.

development.

This includes an inhibitor of Bruton's tyrosine kinase CloseBruton\'s tyrosine kinase

A enzyme CloseEnzyme

A type of protein CloseProtein

A class of molecules (including enzymes, antibodies, or structural proteins) that are built from amino acid components to perform a wide range of functions in the cell.

that catalyzes chemical reactions in the cell.

implicated in the immunodeficiency CloseImmunodeficiencyInherited condition caused mutation in genes that effect immune response. disease X-linked agammaglobulinemia CloseAgammaglobulinemia

A genetic immunosuppressive disease in humans that results from a mutated and inactivated Btk gene.

(XLA). It plays a crucial role in B cell maturation and mast cell CloseMast Cell

Cells involved in allergic and inflammatory response.

activation.

(Btk) (PCI-32765) currently in a Phase I clinical trial ClosePhase I Clinical Trial

One step in the drug approval process during which doctors establish the safety of a new drug and its best dose, administration, and regimen.

targeting oncology CloseOncologyThe study and treatment of cancer. applications; a series of Btk inhibitors in advanced preclinical lead optimization and testing targeting autoimmune CloseAutoimmune

An immune response by the body against its own cells or tissues.

and allergic indications; an inhibitor of Factor VIIa CloseFactor VIIa, Factor IXa, Factor Xa, Factor XI

A series of coagulation factors that circulate outside the blood stream and in the environment surrounding tumors.

(PCI-27483) soon to be in a Phase I/II clinical trial; a histone deacetylase inhibitor (PCI-24781) about to enter a Phase II clinical trial; ClosePhase II Clinical TrialIn this phase of testing, doctors try to confirm the safety and dosing of the new drug as well as its effectiveness. and HDAC8 inhibitors (i.e PCI-34051 and others) that are currently being optimized for autoimmune and cancer indications. Motexafin gadolinium (MGd) has completed accrual in two Phase II trials being conducted by the National Cancer Institute (NCI) in patients with glioblastoma multiforme and pontine glioma.